Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
Drugs by status
Approved for this indication (4)
Phase 4 trials (40)
- efavirenz
- abacavir
- maraviroc
- stavudine
- ethambutol
- mesalamine
- dolutegravir
- tenofovir
- ritonavir
- rifampin
- icosapent ethyl
- lamivudine
- levocarnitine
- leucovorin
- nevirapine
- pyrazinamide
- lopinavir
- buprenorphine
- sulfamethoxazole
- emtricitabine
- darunavir
- fluconazole
- vardenafil
- thiamine
- sulfadoxine
- zidovudine
- methadone
- adenosma glutinosum
- eclipta prostrata
- raltegravir
- +10 more
Phase 3 trials (20)
Phase 2 trials (40)
- thalidomide
- vitamin d3
- ags-004
- aldoxorubicin
- epoetin
- cidofovir
- alpha-lipoic acid
- dapivirine
- dimiracetam
- etravirine
- naltrexone
- gsk732462
- gsk732461
- aldesleukin
- pembrolizumab
- pgt121
- psg2.hivconsv dna vaccine
- risankizumab
- cannabis
- ad26.mos.hiv
- ad35-grin
- hiv vaccine 732461
- tat oyi
- trivalent mrkad5 hiv-1 gag/pol/nef
- autologous mesenchymal stem cells
- allogeneic blood cells
- chloroquine
- hiv clade b'/c dna vaccine
- recombinant vaccinia virus rtv
- cytotoxic t cells
- +10 more
Phase 1 trials (19)
- amprenavir
- apl 400-003
- busulfan
- hiv glycoprotein cn54gp140 vaccine
- indinavir
- afo-18
- polyacrylamide
- sunitinib
- interleukin-12
- syngeneic lymphocytes cultured with okt3 and interleukin-2
- ad5-gag
- modified vaccinia ankara hiv vaccine
- m-gpe
- pclus 3-18 mn
- pclus 6.1 mn
- telaprevir
- shRNA-modified CD34+ cells
- uvax-1107
- uvax-1197
Organizations
Organization Involved with Phase 4 Indications (127)
- Abbott
- AbbVie
- Napo Pharmaceuticals
- Bristol-Myers Squibb
- Bausch Health Companies
- Roche
- Gilead Sciences
- ViiV Healthcare
- Merck
- Pfizer
- GlaxoSmithKline
- Pronova BioPharma
- Boehringer Ingelheim
- Fundacion SEIMC-GESIDA
- PETHEMA Foundation
- St. Hope Foundation
- Fundacio Lluita Contra la SIDA
- National Institutes of Health (NIH)
- Medical Research Council
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute on Drug Abuse (NIDA)
- Rodwick, Barry M., M.D.
- Hospital San Carlos, Madrid
- Hebei University
- Baylor University
- Boston University
- Brown University
- Harvard University
- Duke University
- +97 more
Organization Involved with Phase 3 Indications (105)
- PPD
- Schering-Plough
- Merck Serono
- Grifols
- Sanofi
- Sanofi-Aventis
- Shionogi
- Tibotec
- Avexa
- Biocad
- CONRAD
- Endo Pharmaceuticals
- Glaxo Wellcome
- OXO Chemie
- Shaman Pharmaceuticals
- The Immune Response Corporation
- VaxGen
- Westat
- CytoDyn, Inc.
- PharmaResearch
- PENTA Foundation
- French National Agency for Research on AIDS and Viral Hepatitis
- National Cancer Institute (NCI)
- National Eye Institute (NEI)
- National Institute of Mental Health (NIMH)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Willem Daniel Francois Venter
- University of Pennsylvania
- CIHR Canadian HIV Trials Network
- Chulalongkorn University
- +75 more
Organization Involved with Phase 2 Indications (116)
- Abivax S.A.
- Incyte
- Achillion Pharmaceuticals
- Celgene
- Amgen
- MedImmune
- Genzyme
- Progenics
- Mylan
- Novartis
- AmpliPhi Biosciences Corporation
- Argos Therapeutics
- Bavarian Nordic
- Bayer
- Biocodex
- Calimmune, Inc.
- Hoechst Marion Roussel
- Inovio Pharmaceuticals
- International Partnership for Microbicides, Inc.
- Neurotune AG
- Ortho Biotech, Inc.
- Parexel
- Tobira Therapeutics, Inc.
- Frontier Biotechnologies Co., Ltd.
- The EMMES Corporation
- Viriom
- AIDS Clinical Trials Group
- FHI 360
- International AIDS Vaccine Initiative
- Desmond Tutu HIV Centre
- +86 more
Organization Involved with Phase 1 Indications (52)
- Zeria Pharmaceutical
- Jacobus Pharmaceutical
- Chiron
- Sandoz
- Protein Sciences Corp
- Genentech
- Purdue Pharmaceuticals
- Alkermes
- Argus Pharmaceuticals
- Auritec Pharmaceuticals
- G D Searle
- Kainos Medicine Inc.
- Laboratorio Elea S.A.C.I.F. y A.
- Lexigen Pharmaceuticals
- Avid Bioservices
- Otsuka
- Starpharma Pty Ltd
- EuroVacc Foundation
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Centers for Disease Control and Prevention, China
- National Human Genome Research Institute (NHGRI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Changi General Hospital
- Temple University
- Guangzhou Medical University
- Hospital Italiano de Buenos Aires
- Research Institute for Genetic and Human Therapy
- St Stephens Aids Trust
- The Honolulu Medical Group
- Thomas Jefferson University
- +22 more
Organization Involved with Other Experimental Indications (43)
- CSL Behring
- Lederle
- Agouron
- Astra
- Newport Pharmaceuticals International
- Taiwan Liposome Company
- Lyphomed, Inc.
- EngenderHealth
- Planned Parenthood
- National Institute for Medical Research, Tanzania
- University of Roma La Sapienza
- American Heart Association
- Catholic University of Health and Allied Sciences
- China Academy of Chinese Medical Sciences
- Federal University of Rio Grande do Sul
- Hacettepe University
- Istituto Superiore di Sanità
- Medical College of Wisconsin
- Réseau Africain de Recherche sur le SIDA
- University of Cambridge
- University of Vienna
- Fenway Health
- Hebrew University
- Hennepin Healthcare
- MACC Fund Research Center
- Universidad Autonoma de Barcelona
- Cantonal Hospital of St. Gallen
- Uganda AIDS Commission
- The Swedish Research Council
- Kenya National AIDS & STI Control Programme
- +13 more